Clinical presentation, national practice patterns, and outcomes of breast adenomyoepithelioma

• DOI: 10.1111/tbj.13638
• Publication Date: 2019-10-03T05:02:57Z
• Authors: Waqar Haque; Vivek Verma; Vickie Suzanne Kl...; Julie Nangia; Mary Schwartz; Edward Brian Butler; Bin S. Teh
• Keywords: Lumpectomy; Hormonal Therapy

Breast adenomyoepithelioma (AME) is a rare tumor with the published literature mainly in form of case reports. Thus, there currently only limited data to guide evidence-based management. We sought use large, contemporary US database evaluate how these patients are managed and describe expected outcomes. The National Cancer Database was queried (2004-2013) for women AME. Statistics included multivariable logistic regression, Kaplan–Meier analysis overall survival (OS) Cox proportional hazards modeling. Overall, 110 were analyzed. At diagnosis, median age 67 years size 2.0 cm. All but four had node-negative disease. A majority (55%) tumors estrogen receptor negative, one positive HER2/neu. most common surgical procedure lumpectomy (60%); minority (10.9%) subjects underwent complete axillary nodal dissection, one-quarter not undergoing pathologic sampling. Chemotherapy, hormonal therapy, radiotherapy utilized (26%, 8%, 36%, respectively), none associated OS. follow-up 52 months, 5-year OS entire population 74.4%. Disease-related characteristics practice patterns described AME, largest study this date. Resection important aspect management, based on dataset low rate involvement suggests that some cases sampling could be safely omitted. Adjuvant therapy may considered case-by-case basis. Taken together, provide valuable insight into neoplasm better inform management patients.